NL-OMON34869已完成不适用
PharmacoKINEtics of TAMoxifen and its metabolites in breast cancer patients: the influence of a dose increase in phenotypic poor metabolizers of CYP2D6 (KINETAM) - KINETAM
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Subject is at least 18 years at screening
- •2. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- •3. Subject is a female patient with (a history of) breast cancer; has been treated with tamoxifen 20mg QD for at least 4 weeks and is expected to be treated for at least another 4 weeks.
排除标准
- •1. Inability to understand the nature and extent of the trial and the procedures required.
- •2. Participation in a drug trial within 60 days prior to the first dose.
研究者
相似试验
招募中
1 期
Pharmacokinetics and pharmacogenomics of Tamoxifen in healthy volunteers: The effects of African specific CYP2D6*17 genotype on the plasma levels of Tamoxifen and its metabolitesCancerPACTR202106791732070AiBST42
已完成
1 期
PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)Breast CancerNCT01192308Radboud University Medical Center42
已完成
不适用
Clinical pharmacology of tamoxifen in breast cancer patientsPersonal history of malignant neoplasm of breastZ85.3RBR-7tqc7kFaculdade de Ciências Farmacêuticas de Ribeirão Preto
已完成
不适用
STUDY OF TAMOXIFEN AND EXEMESTANE MORE GNRH ANALOGUE AS ADJUVANT THERAPY FOR PREMENOPAUSIC WOMEN WITH BREAST CANCER WITH ENDOCRINE RESPONSE-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-069-03INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,
尚未招募
4 期
A study to find best medicine and its dose for the treatment of breast pain.CTRI/2018/02/012043HLL lifecare Ltd